Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 28;11(9):1567.
doi: 10.3390/diagnostics11091567.

Performance of Seven SARS-CoV-2 Self-Tests Based on Saliva, Anterior Nasal and Nasopharyngeal Swabs Corrected for Infectiousness in Real-Life Conditions: A Cross-Sectional Test Accuracy Study

Affiliations

Performance of Seven SARS-CoV-2 Self-Tests Based on Saliva, Anterior Nasal and Nasopharyngeal Swabs Corrected for Infectiousness in Real-Life Conditions: A Cross-Sectional Test Accuracy Study

Miroslav Homza et al. Diagnostics (Basel). .

Abstract

Many studies reported good performance of nasopharyngeal swab-based antigen tests for detecting SARS-CoV-2-positive individuals; however, studies independently evaluating the quality of antigen tests utilizing anterior nasal swabs or saliva swabs are still rare, although such tests are widely used for mass testing. In our study, sensitivities, specificities and predictive values of seven antigen tests for detection of SARS-CoV-2 (one using nasopharyngeal swabs, two using anterior nasal swabs and four using saliva) were evaluated. In a setting of a high-capacity testing center, nasopharyngeal swabs for quantitative PCR (qPCR) were taken and, at the same time, antigen testing was performed in accordance with manufacturers' instructions for the respective tests. In samples where qPCR and antigen tests yielded different results, virus culture was performed to evaluate the presence of the viable virus. Sensitivities and specificities of individual tests were calculated using both qPCR and qPCR corrected for viability as the reference. In addition, calculations were also performed for data categorized according to the cycle threshold and symptomatic status. The test using nasopharyngeal swabs yielded the best results (sensitivity of 80.6% relative to PCR and 91.2% when corrected for viability) while none of the remaining tests (anterior nasal swab or saliva-based tests) came even close to the WHO criteria for overall sensitivity. Hence, we advise caution when using antigen tests with alternative sampling methods without independent validation.

Keywords: COVID-19; SARS-CoV-2; anterior nasal swab; evaluation; qPCR; rapid antigen tests; saliva; virus culture.

PubMed Disclaimer

Conflict of interest statement

Tests were provided by the distributors of the tests who also contributed equally to the costs of testing. However, the funders had no role in the design of the study; in the collection, analyses and interpretation of data; or in the writing of the article. However, under the terms of the agreements with the funders, without which this study could not be performed at all, we are not allowed to publish the test names or manufacturers.

Figures

Figure 1
Figure 1
Sensitivities of individual tests calculated relative to qPCR as the gold standard, and presence of viable virus stratified by Ct cycles; note that cell culture was performed only in 488 samples where qPCR and RAT test results differed; where the respective category included fewer than 5 patients, data are not presented in the graph. NPS–nasopharyngeal swab; ANS–anterior nasal swab; Ct–Cycle threshold.
Figure 2
Figure 2
Sensitivities of individual tests with qPCR corrected for the culture results used as the gold standard (see Methods for more information) stratified by Ct cycles; where the respective category included fewer than 5 patients, data are not presented in the graph. NPS–nasopharyngeal swab; ANS–anterior nasal swab; Ct–Cycle threshold.

Similar articles

Cited by

References

    1. ECDC . Options for the Use of Rapid Antigen Tests for COVID-19 in the EU/EEA and the UK. ECDC; Solna Municipality, Sweden: 2020.
    1. Brümmer L.E., Katzenschlager S., Gaeddert M., Erdmann C., Schmitz S., Bota M., Grilli M., Larmann J., Weigand M.A., Pollock N.R., et al. The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. medRxiv. 2021 doi: 10.1101/2021.02.26.21252546. - DOI - PMC - PubMed
    1. Dinnes J., Deeks J.J., Adriano A., Berhane S., Davenport C., Dittrich S., Emperador D., Takwoingi Y., Cunningham J., Beese S., et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 2020;8:CD013705. doi: 10.1002/14651858.cd013705. - DOI - PMC - PubMed
    1. Scheiblauer H., Filomena A., Nitsche A., Puyskens A., Corman V.M., Drosten C., Zwirglmaier K., Lange C., Emmerich P., Müller M., et al. Comparative sensitivity evaluation for 122 CE-marked SARS-CoV-2 antigen rapid tests. medRxiv. 2021 doi: 10.1101/2021.05.11.21257016. - DOI - PMC - PubMed
    1. ECDC ECDC Technical Report: Considerations Onthe Use of Self-Testsfor COVID-19 in the EU/EEA. [(accessed on 6 June 2021)]. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/Considerations-....

LinkOut - more resources